C4 Therapeutics, Inc. Increase (Decrease) in Deferred Revenue
C4 Therapeutics, Inc. (CCCC) reported Increase (Decrease) in Deferred Revenue of $12.04 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2026-08-11
- C4 Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2026-06-30 was $14.81M.
- C4 Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2026-03-31 was -$2.77M.
- C4 Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-12-31 was -$8.68M.
- C4 Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-09-30 was -$6.76M.
- C4 Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2025 was -$18.84M, a 290.57% decline from fiscal 2024.
- C4 Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2024 was $9.88M, a 162.04% increase from fiscal 2023.
- C4 Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2023 was $3.77M.
- C4 Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2022 was -$22.65M.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $12.04M 10-Q · filed 2026-08-11 | $3.36M derived: sum of 3 quarters · filed 2026-08-11 | -$3.40M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$2.77M 10-Q · filed 2026-05-12 | -$11.45M derived: sum of 2 quarters · filed 2026-05-12 | -$18.21M derived: sum of 3 quarters · filed 2026-05-12 | -$21.14M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$8.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$15.44M derived: sum of 2 quarters · filed 2026-02-26 | -$18.37M derived: sum of 3 quarters · filed 2026-08-11 | -$18.84M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$6.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$9.69M derived: sum of 2 quarters · filed 2026-08-11 | -$10.15M 10-Q · filed 2025-11-06 | -$12.40M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$2.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$3.40M 10-Q · filed 2026-08-11 | -$5.65M derived: sum of 3 quarters · filed 2026-08-11 | -$9.73M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$467.00K 10-Q · filed 2026-05-12 | -$2.72M derived: sum of 2 quarters · filed 2026-05-12 | -$6.80M derived: sum of 3 quarters · filed 2026-05-12 | -$9.15M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$2.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$6.33M derived: sum of 2 quarters · filed 2026-02-26 | -$8.68M derived: sum of 3 quarters · filed 2026-02-26 | $9.88M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$4.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$6.43M derived: sum of 2 quarters · filed 2025-11-06 | $12.13M 10-Q · filed 2025-11-06 | $21.37M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$2.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $16.22M 10-Q · filed 2025-08-07 | $25.45M derived: sum of 3 quarters · filed 2025-08-07 | $14.88M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $18.56M 10-Q · filed 2025-05-07 | $27.80M derived: sum of 2 quarters · filed 2025-05-07 | $17.23M derived: sum of 3 quarters · filed 2025-05-07 | $25.07M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $9.24M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$1.33M derived: sum of 2 quarters · filed 2025-02-27 | $6.50M derived: sum of 3 quarters · filed 2025-02-27 | $3.77M 10-K · filed 2025-02-27 |
| 2023-09-30 | -$10.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$2.74M derived: sum of 2 quarters · filed 2024-10-31 | -$5.47M 10-Q · filed 2024-10-31 | -$6.85M derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-06-30 | $7.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $5.11M 10-Q · filed 2024-08-01 | $3.73M derived: sum of 3 quarters · filed 2024-08-01 | -$1.54M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | -$2.73M 10-Q · filed 2024-05-08 | -$4.11M derived: sum of 2 quarters · filed 2024-05-08 | -$9.38M derived: sum of 3 quarters · filed 2024-05-08 | -$19.50M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$6.65M derived: sum of 2 quarters · filed 2024-02-22 | -$16.77M derived: sum of 3 quarters · filed 2024-02-22 | -$22.65M 10-K · filed 2024-02-22 |
| 2022-09-30 | -$5.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | -$15.39M derived: sum of 2 quarters · filed 2023-11-01 | -$21.27M 10-Q · filed 2023-11-01 | -$36.34M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | -$10.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$16.01M 10-Q · filed 2023-08-08 | -$31.07M derived: sum of 3 quarters · filed 2023-08-08 | -$34.72M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$5.88M 10-Q · filed 2023-05-04 | -$20.94M derived: sum of 2 quarters · filed 2023-05-04 | -$24.60M derived: sum of 3 quarters · filed 2023-05-04 | -$27.16M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | -$15.06M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$18.71M derived: sum of 2 quarters · filed 2023-02-23 | -$21.28M derived: sum of 3 quarters · filed 2023-02-23 | -$25.05M 10-K · filed 2023-02-23 |
| 2021-09-30 | -$3.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$6.22M derived: sum of 2 quarters · filed 2022-11-03 | -$9.99M 10-Q · filed 2022-11-03 | -$13.77M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$2.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$6.34M 10-Q · filed 2022-08-04 | -$10.12M derived: sum of 3 quarters · filed 2022-08-04 | -$14.42M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | -$3.77M 10-Q · filed 2022-05-05 | -$7.55M derived: sum of 2 quarters · filed 2022-05-05 | -$11.85M derived: sum of 3 quarters · filed 2022-05-05 | -$12.98M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | -$3.78M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$8.08M derived: sum of 2 quarters · filed 2022-02-24 | -$9.21M derived: sum of 3 quarters · filed 2022-02-24 | -$12.20M 10-K · filed 2022-02-24 |
| 2020-09-30 | -$4.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$5.43M derived: sum of 2 quarters · filed 2021-11-10 | -$8.43M 10-Q · filed 2021-11-10 | -$11.26M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | -$1.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | -$4.12M 10-Q · filed 2021-08-11 | -$6.96M derived: sum of 3 quarters · filed 2022-02-24 | |
| 2020-03-31 | -$3.00M 10-Q · filed 2021-05-13 | -$5.83M derived: sum of 2 quarters · filed 2022-02-24 | ||
| 2019-12-31 | -$2.84M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$3.23M 10-K · filed 2022-02-24 | ||
| 2019-09-30 | -$398.00K 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |